Nima Farzan, Kinnate Biopharma CEO
November 15, 2023 06:04 PM ESTUpdated November 16, 12:16 AM
Deals

In­vestors Or­biMed and Fore­site say they're look­ing at tak­ing Kin­nate pri­vate, fol­low­ing pipeline and staff cuts

Kyle LaHucik

Senior Reporter

Kin­nate Bio­phar­ma’s stock $KNTE soared 59% on Wednes­day af­ter­noon af­ter the Cal­i­for­nia drug de­vel­op­er dis­closed that two large share­hold­ers have ex­pressed …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump picks vac­cine skep­tic Kennedy to lead HHS, in what would be an up­heaval of US health pol­i­cy

Eu­ro­pean drug reg­u­la­tor re­vers­es opin­ion on Ei­sai and Bio­gen's Alzheimer's drug

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Gilead will close Philadel­phia, Seat­tle of­fices as part of job re­duc­tions

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times